ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1302

Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF89617) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis

Ichiro Miki1 and Masako Uchii2, 1Fuji Research Park, Kyowa Hakko Kirin, Co., Ltd., Shizuoka, Japan, 2Fuji Research Park, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: adjuvant arthritis, animal models and rheumatoid arthritis, DMARDs, pharmacology, rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Animal Models I

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Kinesins are family of motor proteins that are involved in mitosis and intracellular transport of vesicles and organelles. The mitotic kinesin, Eg5, acts during mitosis and centrosome separation. Selective inhibitors of Eg5 would be expected to be growth inhibition of inflammatory cells and synovial cells undergoing cell division. Litronesib (KF89617, LY2523355) is a newly synthesized compound at Kyowa Hakko Kirin. Litronesib is an ATP-noncompetitive, allosteric, reversible inhibitor of Eg5 that has no observed effect on microtubule formation. Litronesib has been investigated in clinical trials for the treatment of multiple cancers by Eli Lilly and Company. Remission of rheumatoid arthritis with a mitotic inhibitor taxol in patient with breast carcinoma was reported.  In this study, we investigate the anti-rheumatoid activities of Litronesib on animal models of rheumatoid arthritis.

Methods:  The effect of Litronesib was tested on rat adjuvant-induced arthritis (AIA) and mouse collagen-induced arthritis (CIA). KF89617 (Litronesib) or KF88373 (L-aspartate of the racemic mixture of KF89617 and its enantiomer) was synthesized in our laboratories. Mycobacterium butyricum was intradermally injected into the right hind footpad of Lewis rats (8 weeks, female), and AIA was induced. KF88373 was intravenously administered twice a week at 2 mg/kg from the day of the immunization with the adjuvant. Type 2 collagen (CII) with Freund’s complete adjuvant was intradermally injected at the base of the tail of DBA/1J mice (7 weeks, male), and CIA was induced. KF88373 at 4 mg/kg was subcutaneously administered twice a week from the day of the 2nd immunization with CII. KF89617 or KF88373 were orally administered twice a week from the day of the 2nd immunization with CII.

Results:  In rat AIA, KF88373 at 2 mg/kg i.v. twice/week markedly inhibited the swelling of adjuvant-non-treated foot at 78.9% (p<0.01) on Day 21. The inhibitory activity of KF88373 was similar to that of MTX (0.1 mg/kg p.o. 5 times/week) on rat AIA. Inhibition of swelling of adjuvant-injected foot was 21.4% (p<0.05) which was less effective than that of of adjuvant-non-treated foot.  Body weight loss by the induction of AIA was also improved by the treatment of KF88373 but was not by the treatment of MTX.  In mouse CIA, KF88373 at 4 mg/kg s.c. twice/week markedly inhibited the arthritis score at 97.7% (p<0.001) on Day 35. Body weight loss by the induction of CIA was also improved by the treatment of KF88373.  Effect of orally administered KF89617 was tested on CIA. KF89617 or KF88373 at 4 mg/kg p.o. twice/week, potently inhibited the arthritis score at 90.8% (p<0.001) or 87.1% (p<0.01) on Day 35, respectively. Intraperitoneal administration of Taxol (1 mg/kg i.p. twice/week) inhibited CIA score at 61.0% (p<0.01) which was weaker than that of KF89617.  Taxol did not improve body weight loss.

Conclusion:   KF89617 (Litronesib) is a newly synthesized mitotic kinesin Eg5 inihbitor.  KF89617 and KF88373 markedly reduced joint inflammation on both rat AIA and mouse CIA. KF89617 and KF88373 showed pharmacological activities on various administration rute such as p.o., i.v. and s.c. The treatment of KF89617 is expected to provide a novel treatment of rheumatoid arthritis.


Disclosure:

I. Miki,

Kyowa Hakko Kirin,

3,

Kyowa Hakko Kirin,

1;

M. Uchii,

Kyowa Hakko Kirin,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/application-of-cytostatic-agent-kinesin-eg5-inhibitor-litronesib-kf89617-on-rat-adjuvant-induced-arthritis-and-mouse-type-ii-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology